• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by GENFIT S.A.

    5/1/23 4:00:10 PM ET
    $GNFT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $GNFT alert in real time by email
    SC 13G 1 o424232sc13g.htm

     

    Securities and Exchange Commission

    Washington, DC 20549

     

    SCHEDULE 13G

     

     

    Under the Securities Exchange Act of 1934

    (Amendment No. )*

     

     

    Genfit S.A.

    (Name of Issuer)

     

    Ordinary Shares, nominal value €0.25 per share

    (Title of Class of Securities)

     

     

     

    372279109**

    (CUSIP Number)

     

     

     

    April 20, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨       Rule 13d-1(b)

     

    x       Rule 13d-1(c)

     

    ¨       Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    **This CUSIP number applies to the American Depository Shares (“ADSs”) of the Issuer, which are quoted on the Nasdaq Global Select Market under the symbol “GNFT.” Each ADS represents one ordinary share. No CUSIP has been assigned to the ordinary shares.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    Page 1 of 8 Pages
     

     

    CUSIP No. 372279109

     

     

    13G Page 2 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL PARTNERS, LP

     

    2

    Check the Appropriate Box if a Member of a Group*

     

     

    (a) ¨
    (
    b) ý
    3

    SEC Use Only

     

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,643,147

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    2,643,147

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,643,147

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.3%

     

    12

    type of reporting person

     

    pN

     

     

    Page 2 of 8 Pages
     

     

    CUSIP No. 372279109

     

     

    13G Page 3 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    TANG CAPITAL MANAGEMENT, LLC

     

    2

    Check the Appropriate Box if a Member of a Group*

     

     

    (a) ¨
    (
    b) ý
    3

    SEC Use Only

     

     

    4

    Citizenship or Place of Organization

     

    DELAWARE

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,643,147

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    2,643,147

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,643,147

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.3%

     

    12

    type of reporting person

     

    OO

     

     

    Page 3 of 8 Pages
     

     

    CUSIP No. 372279109

     

     

    13G Page 4 of 8 Pages

    1

    NameS of Reporting Persons
    I.R.S. Identification NOS. of Above Persons (ENTITIES ONLY)

     

    KEVIN TANG

     

    2

    Check the Appropriate Box if a Member of a Group*

     

     

    (a) ¨
    (
    b) ý
    3

    SEC Use Only

     

     

    4

    Citizenship or Place of Organization

     

    united states

     

     

    Number of

    5

    Sole Voting Power

    0

     

    Shares

    BENEFICIALLY
    Owned by

    6

    Shared Voting Power

     

    2,643,147

    Each Reporting
    Person with
    7

    Sole Dispositive Power

     

    0

     

      8

    Shared Dispositive Power

     

    2,643,147

     

    9

    Aggregate Amount Beneficially Owned by each Reporting Person

     

    2,643,147

     

    10

    Check Box if the Aggregate Amount in Row (9) excludes certain shares

     

    ¨

    11

    Percent of Class represented by amount in row 9

     

    5.3%

     

    12

    type of reporting person

     

    IN

     

     

    Page 4 of 8 Pages
     

     

    Item 1(a).Name of Issuer:

     

    Genfit S.A. (the “Issuer”)

     

    Item 1(b).Address of Issuer’s Principal Executive Offices:

     

    Parc Eurasante, 885 Avenue Eugene Avinee, Loos, 59120 France 

     

    Item 2(a).Name of Person Filing:

     

    This Statement on Schedule 13G (this “Statement”) is filed by Tang Capital Partners, LP (“Tang Capital Partners”); Tang Capital Management, LLC, the general partner of Tang Capital Partners (“Tang Capital Management”); and Kevin Tang, the manager of Tang Capital Management.

     

    Item 2(b).Address of Principal Business Office or, if none, Residence:

     

    4747 Executive Drive, Suite 210, San Diego, CA 92121

     

    Item 2(c).Citizenship:

     

    Tang Capital Partners is a Delaware limited partnership. Tang Capital Management is a Delaware limited liability company. Mr. Tang is a United States citizen.

     

    Item 2(d).Title of Class of Securities:

     

    Ordinary Shares, nominal value €0.25 per share (the “Ordinary Shares”)

     

    Item 2(e).CUSIP Number: 372279109

     

    Item 3.Not applicable.

     

    Item 4.Ownership.

     

    (a)       Amount Beneficially Owned:

     

    Tang Capital Partners. Tang Capital Partners beneficially owns 2,643,147 of the Issuer’s Ordinary Shares, which consists of: (i) 1,428,489 of the Issuer’s Ordinary Shares and (ii) 1,214,658 of the Issuer’s ADSs, which each represent one Ordinary Share.

     

    Tang Capital Partners shares voting and dispositive power over such shares with Tang Capital Management and Kevin Tang.

     

    Tang Capital Management. Tang Capital Management beneficially owns 2,643,147 of the Issuer’s Ordinary Shares, which consists of: (i) 1,428,489 of the Issuer’s Ordinary Shares and (ii) 1,214,658 of the Issuer’s ADSs, which each represent one Ordinary Share.

     

    Tang Capital Management shares voting and dispositive power over such shares with Tang Capital Partners and Kevin Tang.

     

    Kevin Tang. Kevin Tang beneficially owns 2,643,147 shares of the Ordinary Shares, which consists of: (i) 1,428,489 of the Issuer’s Ordinary Shares and (ii) 1,214,658 of the Issuer’s ADSs, which each represent one Ordinary Share.

     

    Page 5 of 8 Pages
     

     

    Kevin Tang shares voting and dispositive power over such shares with Tang Capital Partners and Tang Capital Management.

     

    The percentages used herein are based on 49,834,983 Ordinary Shares outstanding as of December 31, 2022, as set forth in the Issuer’s Annual Report filed on Form 20-F that was filed with the Securities and Exchange Commission on April 18, 2023.

     

    (b)       Percent of Class:

     

      Tang Capital Partners 5.3%
      Tang Capital Management 5.3%
      Kevin Tang 5.3%

     

    (c)       Number of shares as to which such person has:

     

    (i)       sole power to vote or to direct the vote:

     

      Tang Capital Partners 0 shares
      Tang Capital Management 0 shares
      Kevin Tang 0 shares

     

    (ii)      shared power to vote or to direct the vote:

     

      Tang Capital Partners 2,643,147 shares
      Tang Capital Management 2,643,147 shares
      Kevin Tang 2,643,147 shares

     

    (iii)      sole power to dispose or to direct the disposition of:

     

      Tang Capital Partners 0 shares
      Tang Capital Management 0 shares
      Kevin Tang 0 shares

     

    (iv)      shared power to dispose or to direct the disposition of:

     

      Tang Capital Partners 2,643,147 shares
      Tang Capital Management 2,643,147 shares
      Kevin Tang 2,643,147 shares

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: ¨

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

     

    Not applicable.

     

    Page 6 of 8 Pages
     

     

    Item 8.Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group.

     

    Not applicable.

     

    Item 10.Certification.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    Page 7 of 8 Pages
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

     

    Date: May 1, 2023    
         
         
    TANG CAPITAL PARTNERS, LP  
         
    By:  Tang Capital Management, LLC, its General Partner  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    TANG CAPITAL MANAGEMENT, LLC  
         
         
    By: /s/ Kevin Tang  
      Kevin Tang, Manager  
         
         
    /s/ Kevin Tang  
    Kevin Tang  

     

     

    Page 8 of 8 Pages

     

     

     

    Get the next $GNFT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GNFT

    DatePrice TargetRatingAnalyst
    12/20/2021$8.00Neutral → Buy
    HC Wainwright & Co.
    9/30/2021$8.00 → $7.00Neutral
    HC Wainwright & Co.
    More analyst ratings

    $GNFT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Genfit upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded Genfit from Neutral to Buy and set a new price target of $8.00

      12/20/21 6:28:59 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • HC Wainwright & Co. reiterated coverage on Genfit with a new price target

      HC Wainwright & Co. reiterated coverage of Genfit with a rating of Neutral and set a new price target of $7.00 from $8.00 previously

      9/30/21 6:11:01 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Genfit with a new price target

      SVB Leerink reiterated coverage of Genfit with a rating of Outperform and set a new price target of $15.00 from $20.00 previously

      4/5/21 6:31:27 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Seal Rock Therapeutics Announces Out-Licensing Agreement with GENFIT for Development of Injectable Formulation of SRT-015 for Acute-on-Chronic Liver Disease (ACLF)

      Seal Rock eligible to receive payments up to €100 million, including regulatory, clinical, and commercial milestone payments, plus tiered royalties SEATTLE, May 31, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced it has entered into an out-licensing agreement with GENFIT (Nasdaq and Euronext: GNFT) for the development of an injectable formulation of SRT-015 for acute liver disease, including Acute-on-Chronic Liver Failure (ACLF). Under the agreement, Seal Rock Therapeutic

      5/31/23 4:44:00 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

      Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten

      12/17/21 1:00:00 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by GENFIT S.A. (Amendment)

      SC 13G/A - Genfit S.A. (0001757064) (Subject)

      2/14/24 4:00:25 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by GENFIT S.A.

      SC 13G - Genfit S.A. (0001757064) (Subject)

      5/1/23 4:00:10 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by GENFIT S.A. (Amendment)

      SC 13G/A - Genfit S.A. (0001757064) (Subject)

      2/14/22 6:28:17 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    Financials

    Live finance-specific insights

    See more
    • Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership

      Agreement gives Ipsen global* rights to develop and commercialize GENFIT's late-stage, first-in-class PPAR alpha and delta agonist elafibranor in Primary Biliary Cholangitis (PBC) Investigational treatment elafibranor being evaluated in the global Phase III trial, ELATIVE™, with topline data expected early 2023 GENFIT receives €120m upfront and is eligible to receive up to €360m in milestone payments as well as tiered double-digit royalties of up to 20% Ipsen becomes 8% shareholder of GENFIT via an equity investment of €28m Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216006159/en/ Disclaimer: Inten

      12/17/21 1:00:00 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $GNFT
    SEC Filings

    See more
    • SEC Form 6-K filed by GENFIT S.A.

      6-K - Genfit S.A. (0001757064) (Filer)

      5/7/25 4:10:07 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by GENFIT S.A.

      6-K - Genfit S.A. (0001757064) (Filer)

      5/5/25 6:00:48 AM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 6-K filed by GENFIT S.A.

      6-K - Genfit S.A. (0001757064) (Filer)

      4/29/25 3:10:19 PM ET
      $GNFT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care